Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial - Report - MDSpire

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

  • By

  • Julio Rosenstock

  • Ildiko Lingvay

  • Donna Ryan

  • Ania M. Jastreboff

  • Robert Kushner

  • Andres Acosta

  • Thomas C. Blevins

  • Melissa Choi

  • Faith L. Holmes

  • Timothy Smith

  • Lisa Connery

  • Yao Li

  • Mike Ke Liu

  • Aline Barth

  • Jamie Butcher

  • Antonio Civitarese

  • Huibin Yue

  • Blai Coll

  • June 5, 2026

  • 0 min

Share

Clinical Report: Efficacy of the oral small molecule GLP-1 receptor agonist aleniglipron

Overview

Revise to include specific statistical significance or confidence intervals for weight loss.

Background

Obesity is a growing global health concern associated with increased mortality and comorbidities. GLP-1 receptor agonists (RAs) have emerged as effective treatments for weight management and type 2 diabetes, but access is often limited due to the injectable nature of current therapies. Oral formulations like aleniglipron could enhance accessibility and adherence to obesity treatment.

Data Highlights

Dose (mg)Mean Weight Change (%)95% Confidence Interval
45-9.0-11.2 to -6.8
90-10.7-12.5 to -8.8

Key Findings

  • The study included 230 participants with a mean age of 49.8 years and a mean BMI of 39.5 kg/m².
  • All doses of aleniglipron (45 mg, 90 mg, 120 mg) resulted in statistically significant weight loss compared to placebo.
  • Participants in the 90 mg group achieved a mean weight loss of -10.7% by week 36.
  • Completion rates for the study were similar across aleniglipron and placebo groups, ranging from 73.3% to 78.1%.
  • Safety assessments included treatment-emergent adverse events, with a focus on major adverse cardiovascular events and gastrointestinal issues.

Clinical Implications

The findings suggest that aleniglipron may provide an effective oral option for weight management in individuals with obesity. Clinicians should consider the potential of oral GLP-1 RAs to improve patient adherence and access to obesity treatment.

Conclusion

Aleniglipron shows promise as an effective oral GLP-1 receptor agonist for weight management, warranting further investigation into its long-term safety and efficacy.

Related Resources & Content

  1. Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
  2. JAMA Network Open — Patient Experiences With GLP-1 Receptor Agonists
  3. JAMA Internal Medicine — Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial
  4. JAMA Network Open — HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial
  5. Frontiers in Endocrinology — Glucagon-like peptide-1 receptor agonists and advanced liver outcomes in type 2 diabetes: a systematic review and exploratory meta-analysis
  6. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026
  7. AACE Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update
  8. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
  9. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
  10. Obesity | Nature Medicine
  11. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
  12. Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis - PubMed
  13. Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
  14. Structure touts 16% weight loss 'highest efficacy' for oral GLP1

Original Source(s)

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

  • by Julio Rosenstock, Ildiko Lingvay, Donna Ryan, Ania M. Jastreboff, Robert Kushner, Andres Acosta, Thomas C. Blevins, Melissa Choi, Faith L. Holmes, Timothy Smith, Lisa Connery, Yao Li, Mike Ke Liu, Aline Barth, Jamie Butcher, Antonio Civitarese, Huibin Yue, Blai Coll

  • June 5, 2026

Related Content

Opposing gastric and jejunal regulation of CELA2A in obesity and after Roux-en-Y gastric bypass suggests a role in gastrointestinal metabolic signaling

Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease

Editorial: Vibratory therapy: impacts on endocrine disorders